A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours

This early-phase study tests the safety and tolerability of a new experimental drug called IPN01194 in people with advanced cancers — specifically melanoma, colorectal cancer, pancreatic cancer, or head and neck cancer — whose tumors carry specific genetic mutations. **You may be eligible if...** - You are 18 years or older - You have been diagnosed with one of these advanced cancers: melanoma, colorectal cancer, pancreatic ductal adenocarcinoma, or head and neck squamous cell carcinoma - Your tumor has specific MAPK-related gene mutations - No suitable standard treatment options remain available for you - Your cancer is measurable on imaging scans - You have a good performance status (ECOG 0 or 1) - You are able to provide tumor tissue for testing **You may NOT be eligible if...** - You have a different type of solid tumor not listed above - Your tumor does not have the required genetic mutations - Your general health or organ function does not meet the study requirements Talk to your doctor to see if this trial is right for you.